Systematic identification and validation of novel drug targets from the ubiquitin cascade for the treatment of Her2 amplified breast cancer

泛素级联中用于治疗 Her2 扩增乳腺癌的新药物靶点的系统鉴定和验证

• 批准号: 301041
• 负责人: Turowec Jacob P
• 金额: $ 9.83万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-11-01 至 2016-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=301041&lang=en
• 关键词: Drug Target Discovery; Drug Target Validation; Her2+ Breast Cancer; Phage Display; Pooled Shrna Dropout Screen; Protein Ubiquitylation; Synthetic/Genetic Interactions; Ubiquitin Variants

Her2 is a cancer promoting protein that is over-active in ~25% of breast cancers. Despite therapies that target Her2, this type of breast cancer has a relatively poor prognosis as these tumours often develop resistance, necessitating the need for more eff

Her2是一种促癌蛋白，在约25%的乳腺癌中过度活跃。尽管有靶向Her2的治疗方法，但这种类型的乳腺癌预后相对较差，因为这些肿瘤经常产生耐药性，需要更多的eff